Partners/Collaborators

Strategic Alliances

GlaxoSmithKline

In July 2001, we entered into a worldwide collaboration with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological and gastrointestinal diseases.  Under the terms of this agreement, GSK sponsored and we jointly conducted a collaborative research program and collaborated in the development of our current lead compounds, as well as novel back-up candidates and second generation compounds identified through the collaborative research. The sponsored research portion of this collaboration agreement concluded in 2005. We will be eligible to receive milestone payments as compounds progress through the research and development process, royalties on future product sales and co-promotion rights in the U.S. in some circumstances.

Dainippon Sumitomo Pharma Co. Ltd.

In October 2007, we announced an exclusive license agreement with Dainippon Sumitomo Pharma Co. Ltd. (DSP) to develop and commercialize indiplon in Japan. Under the terms of the agreement DSP is responsible for all development, marketing and commercialization costs of indiplon in Japan. We will be eligible to receive milestone payments upon specified future events related to the development and commercialization of indiplon in Japan. We are also entitled to royalties from DSP on future sales of indiplon in Japan.

In-Licensed Technology:

We have in-licensed the following technologies to complement our ongoing clinical and research programs.

• In July 2007, we licensed exclusive worldwide rights for the development and commercialization of valnoctamide stereoisomers from Yissum Research Development Company of the Hebrew University of Jerusalem, Israel.  Neurocrine plans to develop valnoctamide stereoisomers for neurological and psychiatric diseases.
• In October 2004, we licensed non-exclusive rights to Almirall Prodesfarma’s small molecule adenosine 2A receptor antagonists for the treatment of Parkinson’s Disease.
• In October 2003, we licensed non-exclusive rights to corticotropin releasing factor receptor 2 deficient mice from Research Development Foundation.
• In June, 2003 we licensed a non-exclusive rights to Cav3.1 human cDNA expressing cell line from University of Virginia Patent Foundation
  In May 2003, we entered into a collaboration and license agreement with Bicoll GmbH relating to GPCR targets.
• In March 2003, we licensed a non-exclusive right to certain green fluorescent proteins.
• In January 2003, we licensed exclusive rights to urocortin 2 from Research Development Foundation.
• In December 2002, we licensed knock-out mice to certain target genes from Deltagen, Inc.
• In March 2001, we licensed a HERG cell line from Wisconsin Alumni Research Foundation.
• In August 2000, we licensed non-exclusive rights to CRF R1 deficient mice from the Research Development Foundation.
• In August 1999, we licensed non-exclusive rights to human gonadotropin-releasing hormone receptor from Mount Sinai School of Medicine.
• In June 1998, we licensed exclusive world-wide rights to our sedative compound, indiplon, from Dov Pharmaceutical, Inc.
• In November 1993, we licensed exclusive rights to the CRF receptor from The Salk Institute for Biological Studies.